Ensign Peak Advisors, Inc Arcus Biosciences, Inc. Transaction History

Ensign Peak Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$31.38 - $48.47 $310,034 - $478,883	9,880 New	9,880 $400,000
Q1 2021 May 12, 2021	SELL	$26.16 - $41.39 $417,827 - $661,081	-15,972 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $30,158 - $57,406	-1,774 Reduced 10.0%	15,972 $415,000
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $304,166 - $451,990	17,746 New	17,746 $304,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.